An inflammation tracer that does not need a diet
Deciding whether to put a patient on long-term steroids for heart sarcoidosis depends on a scan that only works if the patient's heart has been starved of sugar for a day, and a biopsy that misses the disease most of the time. A different tracer would not need the diet.
Overview
Cardiac sarcoidosis is the case where the incumbent test's weakness is procedural rather than biological. FDG PET requires metabolic suppression of normal myocardium through a strict low-carbohydrate, high-fat preparation, and imperfect suppression produces false positives on which immunosuppression decisions are then made. The histological reference standard is worse: endomyocardial biopsy sensitivity is reported at approximately 20 to 30%, and elsewhere as less than 25%. There is no reliable serum biomarker for diagnosis, monitoring of inflammatory activity or severity. And the disease is substantially under-recognised: about 5% of sarcoidosis patients have clinically manifest cardiac involvement while autopsy series report 25% to 50%.
Somatostatin receptor tracers are the most developed alternative because macrophages in active granulomas express SSTR2, and no dietary preparation is needed. The evidence is consistent but small and mixed. A University of Pennsylvania study of 11 patients found 91% patient-level concordance with FDG but only 77.1% segment-level agreement, a lower signal-to-blood-pool ratio of 3.2 against 4.9, and underestimation of treatment response. A Würzburg 68Ga-DOTATOC study of 15 patients found SSTR-PET positive in 7 of 15 against cardiac MRI in 10 of 15. A 19-patient comparative study of 68Ga-DOTANOC has been reported at 100% diagnostic accuracy against 79% for FDG, while a 17-patient study found poorer agreement with MRI at 76.5%.
The practical attraction is that the tracer itself is already approved for another indication as NETSPOT, so manufacturing and dosimetry are de-risked; what is missing is a clinical package for this indication, and a completed 78-patient Swedish study with biopsy and MRI comparators is the largest dataset that could supply one.
No non-invasive test reliably establishes whether myocardial inflammation is active right now, because FDG PET depends on imperfect dietary suppression, endomyocardial biopsy has sensitivity of roughly 20 to 30%, and no serum biomarker exists.
- The lower signal-to-blood-pool ratio and underestimated treatment response reported at Pennsylvania could make the agent worse than a well-prepared FDG scan rather than better.
- Segment-level agreement of 77.1% is not adequate for guiding focal decisions such as device placement or ablation.
- Because the tracer is already on the market for another indication, off-label use will absorb the clinical demand and nobody may fund the registrational study.
- Publication of the 78-patient Swedish study, which is the largest dataset and includes biopsy comparison.
- Any macrophage-directed tracer with a better signal-to-background ratio than the somatostatin ligands, which is the specific weakness to beat.
- Guideline language on alternatives to FDG when metabolic suppression fails, which would create the indication a sponsor could file against.
The five domains of a radiopharmaceutical due-diligence review, adapted from the Fryback-Thornbury hierarchy of diagnostic efficacy. Each carries the state of the public evidence and the fact behind it, not a score out of five: a single total hides the reason and stops telling candidates apart. Domains marked as carrying most weight are the ones that decide the case at this asset's stage.
Activated macrophages in sarcoid granulomas express somatostatin receptor 2, giving a specific inflammation target, but signal-to-blood-pool ratio was lower than FDG at 3.2 plus or minus 0.6 against 4.9 plus or minus 1.5.
Five small cohorts, the largest a completed 78-patient Swedish study that also enrolled myocarditis; the published cardiac sarcoidosis series are 11, 15, 17 and 19 patients.
Patient-level concordance with FDG was 91% but segment-level agreement only 77.1% with kappa 0.53; one 19-patient study reported 100% accuracy against 79% for FDG, while a 17-patient study found only 76.5% agreement with MRI.
The tracer is approved as NETSPOT for neuroendocrine tumour localisation, so its manufacturing, safety and dosimetry package already exists; only the cardiac indication is off-label.
No SSTR agent has a cardiac sarcoidosis indication and none has filed for one; the route would be a new indication on an approved molecule, judged against FDG PET and adjudicated diagnosis.
Red, amber or green on each review category, each with its reason, so an obvious no-go takes seconds rather than a meeting.
No dietary preparation is the whole point, but the published signal-to-blood-pool ratio is lower than FDG and treatment response was underestimated in the largest concordance study.
An immunosuppression decision currently rests on a diet-dependent scan and a biopsy with roughly 20 to 30% sensitivity, with no serum biomarker of any kind.
The leading agents are approved generic-era somatostatin ligands; there is no proprietary position to take in DOTATATE itself.
Standalone and repeatable for treatment monitoring, but cardiac sarcoidosis is a small indication and the tracer is already purchasable for another one, so a sponsor would fund a trial for a label it may not be able to protect.
Gallium-68 from a generator, already distributed for neuroendocrine imaging.
The competition is off-label use of an approved tracer, which is cheap and available now and therefore hard to displace with a funded programme.
- University of Pennsylvaniacompleted pilot
68Ga-DOTATATE against FDG in 11 cardiac sarcoidosis patients with follow-up scans in 8; 91% patient-level concordance, 77.1% segment-level.
https://link.springer.com/article/10.1007/s12350-022-03111-4 - Mayo Cliniccompleted
Phase 4 comparison of 68Ga-DOTATATE with FDG and 13N-ammonia PET/CT, 15 patients, completed.
https://clinicaltrials.gov/study/NCT03549598 - Västra Götaland Region, Swedencompleted
68Ga-DOTA-TOC in inflammatory heart disease, 78 participants, against contrast MRI, FDG PET and endomyocardial biopsy; completed June 2024.
https://clinicaltrials.gov/study/NCT04206163 - Würzburg and other academic groupspublished feasibility
68Ga-DOTATOC in 15 patients with biopsy-proven sarcoidosis and suspected cardiac involvement, positive in 7 of 15 against MRI in 10 of 15.
https://pmc.ncbi.nlm.nih.gov/articles/PMC5363622/
Similar pages
not linked directly; found by shared links- RoadmapNeuro-oncology imaging roadmap: FDG PET → amino acid PET → SSTR2 theranostics in meningioma
Shares Fludeoxyglucose F-18 (FDG), Gallium-68 DOTATATE (and Cu-64 DOTATATE), Somatostatin receptor PET (68Ga/64Cu-DOTATATE), FDG PET.
- IndicationFever of unknown origin
Shares Fludeoxyglucose F-18 (FDG), FDG PET, PET/CT and the tag inflammation.
- AgentCopper-64 dotatate
Shares Gallium-68 edotreotide (DOTATOC), Gallium-68 DOTATATE (and Cu-64 DOTATATE), Somatostatin receptor PET (68Ga/64Cu-DOTATATE), Somatostatin receptor 2.
- OpportunityCEACAM5 imaging for occult colorectal recurrence
Shares FDG PET, PET/CT, Fluorine-18, Gallium-68 and the tag unmet need first.
- OpportunityCXCR4 imaging instead of adrenal vein sampling
Shares PET/CT, Gallium-68 and the tags unmet need first, non-oncology.
- OpportunityFAP imaging to stop futile pancreatic surgery
Shares FDG PET, PET/CT, Fluorine-18, Gallium-68 and the tag unmet need first.
- TargetGLUT1 / hexokinase (glucose metabolism)
Shares Fludeoxyglucose F-18 (FDG), FDG PET, Fluorine-18.
- AgentFludeoxyglucose F-18 (brain metabolism)
Shares Fludeoxyglucose F-18 (FDG), FDG PET, Fluorine-18.